Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment that has multiple indications approved by the U.S. Food and Drug Administration (FDA). The confidential arbitration was conducted by a tribunal of three earlier this […]

A federal judge in Delaware tossed out a lawsuit by Roche company Genentech accusing Novartis’ Sandoz division of patent infringement. In this case, the patent was related to Genentech’s Esbriet (pirfenidone), which is used to treat idiopathic pulmonary fibrosis.

Alnylam is suing both Moderna and Pfizer over what it claims are patent infringements related to the Cambridge, Massachusetts-based company’s biodegradable cationic lipids that it says have been foundational to the success of the mRNA-based COVID-19 vaccines developed by the two companies.

AstraZeneca’s rare disease arm Alexion agreed to resolve all patent disputes with Chugai Pharmaceutical regarding the prescription drug Ultomiris (ravulizumab) by signing a settlement agreement that will involve a one-time payment of $775 million. 

Moderna is facing additional challenges to patent the COVID-19 vaccine Spikevax, as Arbutus Biopharma and Genevant filed a lawsuit against the company challenging patent infringement.

In a patent infringement lawsuit filed against Eli Lilly, Teva Pharmaceutical won three and lost six patents. The patent lawsuit was over Teva’s Ajovy (fremanezumab-vfrm) to prevent migraines. Eli Lilly has a competitive migraine drug, Emgality (galcanezumab).

United Therapeutics Corporation announced that the company is pursuing additional claims for trade secret misappropriation against Liquidia Technologies Inc. and a former United Therapeutics employee who later joined Liquidia as an executive.

Merck

The U.S. Supreme Court rejected Merck & Co. Inc.’s bid to revive a $2.54 billion jury verdict the company won against rival drugmaker Gilead Sciences Inc. for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

Catalyst Pharmaceuticals filed new patent infringement lawsuits against Jacobus Pharmaceuticals and PANTHERx Rare LLC over a treatment for the rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS).

Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.